A previous study reported a first Phase 1b clinical trial of an individualized neoantigen-based vaccine (NEO-PV-01) combined with a PD-1 blocker for the treatment of patients with bladder cancer. This evidence concerns the gene PDCD1 and urinary bladder cancer.